Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1.
BACKGROUND/AIMS: Examine the mitoinhibitory effect of the liver tumor promoter 2-acetylaminofluorene (2-AAF) in vivo, with focus on the proteins regulating G1- and S progression. METHODS: cdk 2 kinase assay to examine histone H1 phosphorylation. cdk 4 kinase assay to examine whether active cdk 4/cyclin D complexes, capable of phosphorylating Rb, are formed. Western blot to monitor protein expression. RESULTS: cdk 4 kinase-mediated Rb phosphorylation was increased by AAF treatment. Nuclear expression of the transcription factors E2F-1 and E2F-3 was downregulated, while E2F-4 was decreased. 2-AAF treatment also markedly reduced cdk 2 kinase activity/histone H1 phosphorylation during G1/S-transition. Western blot showed loss of nuclear as well as cytoplasmic cyclin A and cyclin B protein after 2-AAF treatment, while the Rb protein level was markedly increased during G1. The cell cycle dependent elevation of nuclear p107 protein, seen in control livers, was not observed in AAF-treated animals. CONCLUSIONS: Effects of 2-AAF; Very low cdk 2 kinase activity that could possibly block G1/S-transition; increased pRb level together with diminished levels of transcription factors E2F-1 and -3, that could be responsible for reducing the expression of E2F target genes such as cyclin A and E2F-1.[1]References
- Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1. Ohlson, L.C., Koroxenidou, L., Porsch-Hällström, I. J. Hepatol. (2004) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
